These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 32015486)
1. Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer. Rebollido-Rios R; Venton G; Sánchez-Redondo S; Iglesias I Felip C; Fournet G; González E; Romero Fernández W; Borroto Escuela DO; Di Stefano B; Penarroche-Díaz R; Martin G; Ceylan I; Costello R; Perez-Alea M Oncogene; 2020 Mar; 39(13):2756-2771. PubMed ID: 32015486 [TBL] [Abstract][Full Text] [Related]
2. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer. You Q; Guo H; Xu D Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059 [TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. Lei HM; Zhang KR; Wang CH; Wang Y; Zhuang GL; Lu LM; Zhang J; Shen Y; Chen HZ; Zhu L Theranostics; 2019; 9(24):7122-7139. PubMed ID: 31695757 [No Abstract] [Full Text] [Related]
4. Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells. Jiménez R; Pequerul R; Amor A; Lorenzo J; Metwally K; Avilés FX; Parés X; Farrés J Chem Biol Interact; 2019 Jun; 306():123-130. PubMed ID: 30958995 [TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma. Flahaut M; Jauquier N; Chevalier N; Nardou K; Balmas Bourloud K; Joseph JM; Barras D; Widmann C; Gross N; Renella R; Mühlethaler-Mottet A BMC Cancer; 2016 Oct; 16(1):781. PubMed ID: 27724856 [TBL] [Abstract][Full Text] [Related]
6. Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2). Quash G; Fournet G; Chantepie J; Gore J; Ardiet C; Ardail D; Michal Y; Reichert U Biochem Pharmacol; 2002 Oct; 64(8):1279-92. PubMed ID: 12234608 [TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355 [TBL] [Abstract][Full Text] [Related]
8. The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer. Voronkova MA; Rojanasakul LW; Kiratipaiboon C; Rojanasakul Y Mol Cell Biol; 2020 Jan; 40(2):. PubMed ID: 31658996 [TBL] [Abstract][Full Text] [Related]
9. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Moreb JS; Ucar D; Han S; Amory JK; Goldstein AS; Ostmark B; Chang LJ Chem Biol Interact; 2012 Jan; 195(1):52-60. PubMed ID: 22079344 [TBL] [Abstract][Full Text] [Related]
10. ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Pérez-Alea M; McGrail K; Sánchez-Redondo S; Ferrer B; Fournet G; Cortés J; Muñoz E; Hernandez-Losa J; Tenbaum S; Martin G; Costello R; Ceylan I; Garcia-Patos V; Recio JA Oncogene; 2017 Oct; 36(41):5695-5708. PubMed ID: 28581514 [TBL] [Abstract][Full Text] [Related]
11. Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer. Wu S; Zhao Q; Liu S; Kuang J; Zhang J; Onga A; Shen Y; Wang J; Sui H; Ni L; Ye Y; Tu X; Le HB; Zheng Y; Cui R; Zhu W Int J Oncol; 2024 Aug; 65(2):. PubMed ID: 38873997 [TBL] [Abstract][Full Text] [Related]
13. Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells. Croker AK; Rodriguez-Torres M; Xia Y; Pardhan S; Leong HS; Lewis JD; Allan AL Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937653 [TBL] [Abstract][Full Text] [Related]
14. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853 [TBL] [Abstract][Full Text] [Related]
15. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340 [TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase 1A1 and 1A3 isoforms - mechanism of activation and regulation in cancer. Poturnajova M; Kozovska Z; Matuskova M Cell Signal; 2021 Nov; 87():110120. PubMed ID: 34428540 [TBL] [Abstract][Full Text] [Related]
17. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553 [TBL] [Abstract][Full Text] [Related]
18. Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity. Parajuli B; Georgiadis TM; Fishel ML; Hurley TD Chembiochem; 2014 Mar; 15(5):701-12. PubMed ID: 24677340 [TBL] [Abstract][Full Text] [Related]
19. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728 [TBL] [Abstract][Full Text] [Related]
20. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Samson JM; Ravindran Menon D; Smith DE; Baird E; Kitano T; Gao D; Tan AC; Fujita M Chem Biol Interact; 2019 Dec; 314():108822. PubMed ID: 31580832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]